Loading page…
Healthcare
BioMarin Pharmaceutical Inc. maintains an AlphaScore of 61/100 within the healthcare sector as of October 11, 2026. Key metrics include a gross margin of 77.73% and a high price-to-earnings ratio of 148.09, showing strong baseline product profitability alongside an elevated valuation multiple. A key strength is its robust safety subScore of 82. A primary risk is its high P/E ratio of 148.09, reflecting steep earnings pricing.
Written 11/10/2026, 00:41:12 UTC · Snapshot 11/10/2026